Literature DB >> 29914886

Blocking TIR Domain Interactions in TLR9 Signaling.

Artur Javmen1, Henryk Szmacinski2, Joseph R Lakowicz2, Vladimir Y Toshchakov3.   

Abstract

Interaction of TLR9 with ligands activates NF-κB, leading to proinflammatory cytokine production. Excessive TLR activation is a pathogenic factor for inflammatory diseases. This study has examined cell-permeating decoy peptides (CPDPs) derived from the TLR9 Toll/IL-1R resistance (TIR) domain. CPDP 9R34, which included AB loop, β-strand B, and N-terminal BB loop residues, inhibited TLR9 signaling most potently. CPDPs derived from α-helices C, D, and E (i.e., 9R6, 9R9, and 9R11) also inhibited TLR9-induced cytokines but were less potent than 9R34. 9R34 did not inhibit TLR2/1, TLR4, or TLR7 signaling. The N-terminal deletion modification of 9R34, 9R34-ΔN, inhibited TLR9 as potently as the full length 9R34. Binding of 9R34-ΔN to TIR domains was studied using cell-based Förster resonance energy transfer/fluorescence lifetime imaging approach. Cy3-labeled 9R34-ΔN dose-dependently decreased fluorescence lifetime of TLR9 TIR-Cerulean (Cer) fusion protein. Cy3-9R34-ΔN also bound TIRAP TIR, albeit with a lesser affinity, but not MyD88 TIR, whereas CPDP from the opposite TIR surface, 9R11, bound both adapters and TLR9. i.p. administration of 9R34-ΔN suppressed oligonucleotide-induced systemic cytokines and lethality in mice. This study identifies a potent, TLR9-specific CPDP that targets both receptor dimerization and adapter recruitment. Location of TIR segments that represent inhibitory CPDPs suggests that TIR domains of TLRs and TLR adapters interact through structurally homologous surfaces within primary receptor complex, leading to formation of a double-stranded, filamentous structure. In the presence of TIRAP and MyD88, primary complex can elongate bidirectionally, from two opposite ends, whereas in TIRAP-deficient cells, elongation is unidirectional, only through the αE side.
Copyright © 2018 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29914886      PMCID: PMC6057823          DOI: 10.4049/jimmunol.1800194

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  82 in total

1.  HHblits: lightning-fast iterative protein sequence searching by HMM-HMM alignment.

Authors:  Michael Remmert; Andreas Biegert; Andreas Hauser; Johannes Söding
Journal:  Nat Methods       Date:  2011-12-25       Impact factor: 28.547

2.  The pharmacokinetics of cell-penetrating peptides.

Authors:  Dikran Sarko; Barbro Beijer; Regine Garcia Boy; Eva-Maria Nothelfer; Karin Leotta; Michael Eisenhut; Annette Altmann; Uwe Haberkorn; Walter Mier
Journal:  Mol Pharm       Date:  2010-10-07       Impact factor: 4.939

3.  An oligomeric signaling platform formed by the Toll-like receptor signal transducers MyD88 and IRAK-4.

Authors:  Precious G Motshwene; Martin C Moncrieffe; J Günter Grossmann; Cheng Kao; Murali Ayaluru; Alan M Sandercock; Carol V Robinson; Eicke Latz; Nicholas J Gay
Journal:  J Biol Chem       Date:  2009-07-10       Impact factor: 5.157

Review 4.  Assembly and localization of Toll-like receptor signalling complexes.

Authors:  Nicholas J Gay; Martyn F Symmons; Monique Gangloff; Clare E Bryant
Journal:  Nat Rev Immunol       Date:  2014-08       Impact factor: 53.106

5.  cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily.

Authors:  J E Sims; C J March; D Cosman; M B Widmer; H R MacDonald; C J McMahan; C E Grubin; J M Wignall; J L Jackson; S M Call
Journal:  Science       Date:  1988-07-29       Impact factor: 47.728

6.  A Decoy Peptide that Disrupts TIRAP Recruitment to TLRs Is Protective in a Murine Model of Influenza.

Authors:  Wenji Piao; Kari Ann Shirey; Lisa W Ru; Wendy Lai; Henryk Szmacinski; Greg A Snyder; Eric J Sundberg; Joseph R Lakowicz; Stefanie N Vogel; Vladimir Y Toshchakov
Journal:  Cell Rep       Date:  2015-06-18       Impact factor: 9.423

7.  Targeting TLR4 signaling by TLR4 Toll/IL-1 receptor domain-derived decoy peptides: identification of the TLR4 Toll/IL-1 receptor domain dimerization interface.

Authors:  Vladimir Y Toshchakov; Henryk Szmacinski; Leah A Couture; Joseph R Lakowicz; Stefanie N Vogel
Journal:  J Immunol       Date:  2011-03-14       Impact factor: 5.422

8.  Cutting Edge: Differential inhibition of TLR signaling pathways by cell-permeable peptides representing BB loops of TLRs.

Authors:  Vladimir Y Toshchakov; Matthew J Fenton; Stefanie N Vogel
Journal:  J Immunol       Date:  2007-03-01       Impact factor: 5.422

Review 9.  D-galactosamine lethality model: scope and limitations.

Authors:  Richard Silverstein
Journal:  J Endotoxin Res       Date:  2004

Review 10.  Toll-like receptors in the pathogenesis of human disease.

Authors:  Donald N Cook; David S Pisetsky; David A Schwartz
Journal:  Nat Immunol       Date:  2004-10       Impact factor: 25.606

View more
  3 in total

Review 1.  Below the surface: The inner lives of TLR4 and TLR9.

Authors:  Laura Marongiu; Laura Gornati; Irene Artuso; Ivan Zanoni; Francesca Granucci
Journal:  J Leukoc Biol       Date:  2019-03-22       Impact factor: 4.962

2.  A survey of TIR domain sequence and structure divergence.

Authors:  Vladimir Y Toshchakov; Andrew F Neuwald
Journal:  Immunogenetics       Date:  2020-01-30       Impact factor: 2.846

3.  Targeting the TLR signalosome with TIR domain-derived cell-permeable decoy peptides: the current state and perspectives.

Authors:  Vladimir Y Toshchakov; Artur Javmen
Journal:  Innate Immun       Date:  2020-01       Impact factor: 2.680

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.